• The SEC declared Snowdrift Parent's amended registration statement for the Chemomab Therapeutics-Scipher Medicine transaction effective on October 30, 2026.
• Under the July 7, 2026, merger agreement, Chemomab will redomicile to the U.S., with Scipher becoming its wholly owned subsidiary.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004976), on November 03, 2026, and is solely responsible for the information contained therein.